Abstract

Endoscopic screening is premised on the detection of pre-symptomatic, early-stage gastric neoplasia that enables curative resection. Endoscopic screening reduces gastric cancer mortality in high-incidence countries but is highly resource-intensive. Endoscopic surveillance of high-risk subgroups of intestinal metaplasia has gained traction in low and intermediate-incidence countries, and emerging evidence suggests that risk-stratified endoscopic surveillance may facilitate timely detection of cancer. However, outcome-based evidence is required to support its adoption. Yet the impact of an endoscopy-based strategy may well lie in heralding a paradigm that regards every routine diagnostic gastroscopy as an opportunity to screen for GC. Endoscopic surveillance also renders gastric intestinal metaplasia a de facto disease, and the ramification of this needs to be further elucidated.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call